Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer (ELITE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05181826
Recruitment Status : Recruiting
First Posted : January 6, 2022
Last Update Posted : January 6, 2022
Sponsor:
Information provided by (Responsible Party):
Helio Genomics

Brief Summary:
To acquire blood samples from subjects for various purposes, including: i) determining the sensitivity and specificity of select DNA methylation markers for the detection of various types of cancer, ii) identifying benign conditions that may induce false positive or false negative results, and iii) defining the effects of potential interfering substances, such as chemotherapy drugs.

Condition or disease Intervention/treatment
Cancer Liver Cirrhosis Chronic Hepatitis Hepatitis B Hepatitis C Diabetes COPD Diagnostic Test: Multi-analyte Blood Test

Detailed Description:
Whole blood, plasma, and/or serum specimens will be collected from patients with active cancer, patients in cancer remission, patients diagnosed with benign disease, and healthy volunteers. These blood samples will be used to perform various studies to determine the utility of select DNA methylation markers for cancer diagnostic or prognostic indications.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 1200 participants
Observational Model: Other
Time Perspective: Prospective
Official Title: Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer
Actual Study Start Date : May 21, 2019
Estimated Primary Completion Date : February 2023
Estimated Study Completion Date : May 2023



Intervention Details:
  • Diagnostic Test: Multi-analyte Blood Test
    Intend for the qualitative detection of DNA methylation markers for the detection of various types of cancer


Primary Outcome Measures :
  1. Independent performance measure of sensitivity and specificity of a multi-analyte blood test [ Time Frame: 1 month ]
    The primary objective is to measure the performance (sensitivity and specificity) the multi-analyte blood Test for the detection of liver cancers in healthy subjects, subjects diagnosed with active cancer, subjects in cancer remission, and subjects diagnosed with a benign disease.


Secondary Outcome Measures :
  1. To investigate potential endogenous and exogenous interfering substances of a multi-analyte blood test [ Time Frame: 1 Month ]
    To investigate potential endogenous and exogenous interfering substances of a multi-analyte blood test for the detection of liver cancers within healthy subjects, subjects diagnosed with active cancer, subjects in cancer remission, and subjects diagnosed with a benign disease.

  2. Ascertain Reference Range(s) [ Time Frame: 1 Month ]
    Ascertain reference range determination(s) for select CpG methylation sites

  3. Ascertain Sample Stability [ Time Frame: 1 Month ]
    Sample stability under various shipping conditions



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Sampling Method:   Non-Probability Sample
Study Population
Healthy subjects, subjects diagnosed with active cancer, subjects in cancer remission, and subjects diagnosed with a benign disease will eligible to participate in this study.
Criteria

Inclusion Criteria:

2.1.1 Age 18 years or older.

2.1.2 A diagnosis of cancer, cancer remission, benign disease (benign tumor, diabetes, liver cirrhosis, chronic hepatitis B or hepatitis C virus infection, Chronic obstructive pulmonary disease, etc.) or apparently healthy volunteers. .

Exclusion Criteria:

2.2.1 Patients that are unwilling or unable to sign the Informed Consent Form will be excluded.

2.2.2 Approximately 50 mL of blood will be drawn from participants within an 8-week period under this protocol. Patients that have already given 50 mL of blood within this time frame will be excluded.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05181826


Contacts
Layout table for location contacts
Contact: Octavia Reed, BSN, RN 6308578049 octavia@heliohealth.com
Contact: Alamdar Rizvi, MS 6308578049 alamdar@heliohealth.com

Locations
Layout table for location information
United States, California
Torrance Memorial Physician Network - Cancer Care Recruiting
Redondo Beach, California, United States, 90277
Contact: David Chan, MD    310-750-3300      
Sponsors and Collaborators
Helio Genomics
Investigators
Layout table for investigator information
Study Director: Kisha Bush Helio Health
Layout table for additonal information
Responsible Party: Helio Genomics
ClinicalTrials.gov Identifier: NCT05181826    
Other Study ID Numbers: 001-2018
First Posted: January 6, 2022    Key Record Dates
Last Update Posted: January 6, 2022
Last Verified: January 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
DNA Virus Infections
Hepatitis A
Hepatitis C
Hepatitis B
Hepatitis
Liver Cirrhosis
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Infections
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Blood-Borne Infections
Communicable Diseases
Flaviviridae Infections
Hepadnaviridae Infections
Fibrosis
Pathologic Processes